Catalent Inc (NASDAQ:CTLT) shares were down 1.7% on Friday . The stock traded as low as $24.07 and last traded at $24.24, with a volume of 233,759 shares. The stock had previously closed at $24.66.

CTLT has been the topic of several recent research reports. Jefferies Group reaffirmed a “hold” rating and set a $25.00 price objective on shares of Catalent in a report on Friday, June 10th. Bank of America Corp. raised Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Monday, June 20th. They noted that the move was a valuation call. Wells Fargo & Co. raised Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. Finally, Zacks Investment Research raised Catalent from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 5th.

The stock has a 50 day moving average of $23.38 and a 200 day moving average of $25.21. The stock has a market cap of $3.02 billion and a price-to-earnings ratio of 15.06.

In related news, major shareholder Blackstone Management Associat sold 8,785,539 shares of Catalent stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $24.51, for a total transaction of $215,333,560.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Matthew M. Walsh sold 21,197 shares of Catalent stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $28.85, for a total value of $611,533.45. Following the transaction, the insider now owns 105,688 shares of the company’s stock, valued at $3,049,098.80. The disclosure for this sale can be found here.

Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.